Asgpr-binding compounds for the degradation of extracellular proteins
US-2024424108-A1 · Dec 26, 2024 · US
Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
US9505748B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9505748-B2 |
| Application number | US-201314441183-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 7, 2013 |
| Priority date | Nov 8, 2012 |
| Publication date | Nov 29, 2016 |
| Grant date | Nov 29, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound which is or a stereoisomer or pharmaceutically-acceptable salt thereof. 2. A compound according to claim 1 which is or a stereoisomer or pharmaceutically-acceptable salt thereof. 3. A compound according to claim 2 which is or a stereoisomer or pharmaceutically-acceptable salt thereof. 4. A compound according to claim 2 which is or a stereoisomer or pharmaceutically-acceptable salt thereof. 5. A compound according to claim 2 which is or a stereoisomer or pharmaceutically-acceptable salt thereof. 6. A compound according to claim 3 which is or a stereoisomer or pharmaceutically-acceptable salt thereof. 7. A pharmaceutical composition comprising one or more compounds according to claim 1 and a pharmaceutically acceptable carrier or diluent. 8. A pharmaceutical composition comprising a compound according to claim 6 and a pharmaceutically acceptable carrier or diluent. 9. A method of treating a disease, comprising administering to a patient in need of such treatment a therapeutically-effective amount of a compound according to claim 6 wherein the disease is systemic lupus erythematosus.
Assignees
Inventors
Classifications
Drugs for disorders of the blood or the extracellular fluid · CPC title
Immunomodulators · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for immunological or allergic disorders · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9505748B2 cover?
- Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition.
- Who is the assignee on this patent?
- Bristol Myers Squibb Co
- What technology area does this patent fall under?
- Primary CPC classification C07D417/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).